企業プロフィール
Precision BioSciences 株価・ニュース・カタリスト
- ティッカー:
- DTIL
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
7.40 USD (-0.40%)
終値
最終更新: 2026年8月17日
163M USD
時価総額
株価変動の要因
As of Aug 17, 2026, DTIL closed down 0.40% at $7.40. No new same-company headline was identified in the current news window.
企業概要
ARCUS Gene Editing Platform
Precision BioSciences develops in vivo gene-editing therapies using ARCUS nucleases. The compact enzymes are designed for several editing modes, including elimination of viral DNA, excision of defective genomic regions and targeted insertion of functional genetic material.
PBGENE-HBV
PBGENE-HBV is a wholly owned in vivo editing therapy in the Phase 1/2a ELIMINATE-B trial for chronic hepatitis B. It is designed to eliminate covalently closed circular DNA, the source of infectious viral replication, while inactivating integrated HBV DNA.
PBGENE-DMD
PBGENE-DMD uses two ARCUS nucleases delivered in one AAV to excise exons 45 through 55 of the dystrophin gene. The approach is intended to restore a near-full-length functional dystrophin protein in a large subset of patients with Duchenne muscular dystrophy and is entering the Phase 1/2 FUNCTION-DMD trial.
Partnered In Vivo Programs
iECURE is developing ECUR-506, an ARCUS-mediated gene-insertion therapy for neonatal-onset ornithine transcarbamylase deficiency. The OTC-HOPE study is evaluating whether targeted insertion can produce durable metabolic correction.
Partnered Cell Therapy
The allogeneic CAR-T candidate azer-cel is licensed to partners for development in lymphoma, progressive multiple sclerosis and other autoimmune diseases. These programs provide external validation and potential economics from an earlier ex vivo application of ARCUS technology.
今後のカタリスト
- PBGENE-HBV clinical data at the EASL Congress on May 27–30, 2026, with further updates at hepatitis meetings during 2026.
- Initial patient screening at new ELIMINATE-B sites in France and Romania expected in the second quarter of 2026.
- First patient dosing and continued site expansion in the Phase 1/2 FUNCTION-DMD trial.
- ECUR-506 clinical updates at ASGCT and SIMD in May 2026.
- Preliminary Phase 1 azer-cel data in progressive multiple sclerosis expected in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。